PKPD Modeling of VEGF, sVEGFR‐2, sVEGFR‐3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST
Hansson, EK, Amantea, MA, Westwood, P, Milligan, PA, Houk, BE, French, J, Karlsson, MO, Friberg, LE
Published in CPT: pharmacometrics and systems pharmacology (01.11.2013)
Published in CPT: pharmacometrics and systems pharmacology (01.11.2013)
Get full text
Journal Article
526 A Phase I study of the dual, intravenous (IV) phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 in combination with irinotecan in patients (pts) with colorectal cancer (CRC) and other advanced solid tumors
Wainberg, Z, Tabernero, J, Maqueda, M.A, Leong, S, Del Conte, G, Britten, C, Brega, N, Davis, C, Houk, B, Pierce, K, Vermette, J, Siu, L, Brana, I
Published in European journal of cancer (1990) (01.11.2014)
Published in European journal of cancer (1990) (01.11.2014)
Get full text
Journal Article
Pharmacokinetics of plasmid DNA in the rat
HOUK, Brett E, MARTIN, Robin, HOCHHAUS, Günther, HUGHES, Jeffrey A
Published in Pharmaceutical research (2001)
Published in Pharmaceutical research (2001)
Get full text
Journal Article
383 First-in-human study of PF-04691502, a small molecule oral dual inhibitor of PI3K and mTOR in patients with advanced cancer: Preliminary report on safety and pharmacokinetics
Britten, C.D, Adjei, A.A, Millham, R, Houk, B, Wainberg, Z.A, Guthrie, T, Dy, G, LoRusso, P.M
Published in European journal of cancer supplements (2010)
Published in European journal of cancer supplements (2010)
Get full text
Journal Article
387 First-in-human study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: preliminary report on safety and pharmacokinetics
Shapiro, G.I, Molina, J, Bendell, J, Braña, I, Spicer, J, Kwak, E, Pandya, S, Millham, R, Houk, B, Bell-McGuinn, K
Published in European journal of cancer supplements (2010)
Published in European journal of cancer supplements (2010)
Get full text
Journal Article
VP4-2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC
Hochmair, M.J., Vermaelen, K., Mountzios, G., Carcereny, E., Dooms, C., Lee, S-H., Morocz, E.M., Kato, T., Ciuleanu, T-E., Dy, G., Parente, M.B.M.C.S., O'Byrne, K.J., Chu, Q.S-C., De Castro, G., Girard, N., Snyder, W., Tran, Q., Kormany, W., Houk, B., Curioni-Fontecedro, A.
Published in Annals of oncology (01.01.2024)
Published in Annals of oncology (01.01.2024)
Get full text
Journal Article
476PA MODEL RELATING OVERALL SURVIVAL TO TUMOR GROWTH INHIBITION IN RENAL CELL CARCINOMA
Mercier, F., Houk, B., Claret, L., Milligan, P., Bruno, R.
Published in Annals of oncology (01.09.2014)
Published in Annals of oncology (01.09.2014)
Get full text
Journal Article
A Model Relating Overall Survival to Tumor Growth Inhibition in Renal Cell Carcinoma
Mercier, F., Houk, B., Claret, L., Milligan, P., Bruno, R.
Published in Annals of oncology (01.09.2014)
Published in Annals of oncology (01.09.2014)
Get full text
Journal Article
Abstract OT2-07-06: Phase Ib study to assess the safety, tolerability, and clinical activity of gedatolisib in combination with palbociclib and either letrozole or fulvestrant in women with metastatic or locally advanced/recurrent breast cancer (B2151009)
Forero, A, Han, HS, Dees, EC, Wesolowski, R, Bardia, A, Kabos, P, Kern, KA, Perea, R, Pierce, KJ, Houk, B, Rugo, HS
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Published in Cancer research (Chicago, Ill.) (15.02.2018)
Get full text
Journal Article
A Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma: Insights into the Treatment, Efficacy and Safety
Uemura, Hirotsugu, Shinohara, Nobuo, Yuasa, Takeshi, Tomita, Yoshihiko, Fujimoto, Hiroyuki, Niwakawa, Masashi, Mugiya, Soichi, Miki, Tsuneharu, Nonomura, Norio, Takahashi, Masayuki, Hasegawa, Yoshihiro, Agata, Naoki, Houk, Brett, Naito, Seiji, Akaza, Hideyuki
Published in Japanese journal of clinical oncology (01.03.2010)
Published in Japanese journal of clinical oncology (01.03.2010)
Get full text
Journal Article
Overall Survival and Updated Results from a Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma
Tomita, Yoshihiko, Shinohara, Nobuo, Yuasa, Takeshi, Fujimoto, Hiroyuki, Niwakawa, Masashi, Mugiya, Soichi, Miki, Tsuneharu, Uemura, Hirotsugu, Nonomura, Norio, Takahashi, Masayuki, Hasegawa, Yoshihiro, Agata, Naoki, Houk, Brett, Naito, Seiji, Akaza, Hideyuki
Published in Japanese journal of clinical oncology (01.12.2010)
Published in Japanese journal of clinical oncology (01.12.2010)
Get full text
Journal Article
Abstract OT2-3-02: Phase Ib/II study of an oral PI3K/mTOR inhibitor plus letrozole compared with letrozole (L) in pre-operative setting in patients with Estrogen Receptor-positive, HER2-negative early breast cancer (BC): Phase Ib preliminary data
Canon, JL, Bergh, J, Saura, C, Oliveira, M, Houk, B, Millham, R, Barton, J, Dowsett, M, Giorgetti, C
Published in Cancer research (Chicago, Ill.) (15.12.2012)
Published in Cancer research (Chicago, Ill.) (15.12.2012)
Get full text
Journal Article
Phase I study of PF-04554878, a second-generation focal adhesion kinase (FAK) inhibitor, in patients with advanced solid tumors
Jones, S. F., Shapiro, G., Bendell, J. C., Chen, E. X., Bedard, P., Cleary, J. M., Pandya, S., Pierce, K. J., Houk, B., Hosea, N., Zandi, K. S., Roberts, W. G., Shreeve, S. M., Siu, L. L.
Published in Journal of clinical oncology (20.05.2011)
Published in Journal of clinical oncology (20.05.2011)
Get full text
Journal Article
Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/pharmacodynamic (PKPD) approach
Houk, B. E., Bello, C. L., Michaelson, M. D., Bukowski, R. M., Redman, B. G., Hudes, G. R., Wilding, G., Motzer, R. J.
Published in Journal of clinical oncology (20.06.2007)
Published in Journal of clinical oncology (20.06.2007)
Get full text
Journal Article